Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Sponsor: Stemline Therapeutics, Inc.
Listed as NCT02113982, this PHASE1/PHASE2 trial focuses on Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and remains completed. Sponsored by Stemline Therapeutics, Inc., it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
May 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Mar 2020 — May 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2018 — Mar 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Oct 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2017 — Dec 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Stemline Therapeutics, Inc.
- The Leukemia and Lymphoma Society
For direct contact, visit the study record on ClinicalTrials.gov .